Skip to main content
Premium Trial:

Request an Annual Quote

Bayer, Millennium Expand Deal to Include More Diseases

NEW YORK, Sept. 19 – Bayer and Millennium Pharmaceuticals said Wednesday they had extended their alliance to look for new drug targets to battle thrombosis, urinary incontinence, and benign prostatic hypertrophy. 

The companies, which began working together in 1998 and have until now focused on cardiovascular diseased, cancer, pain, hematology, and viral infections, said they have so far identified more than 140 potential drug targets.

One of the compounds the companies have developed is scheduled to enter clinical testing soon, they said. The companies did not disclose the disease the treatment targets.

"Our current success rate for developing targets into lead structures makes us optimistic that we will reach our goal of 30 development candidates," Wolfgang Hartwig, executive vice president of pharmaceuticals research at Bayer, said in a statement. "Our collaboration has proven that genomic technologies are a successful method of finding new lead structures.”

In return for total payments of up to $465 million over a five-year period, Bayer receives access to key technologies in genome research and a flow of new genomics -based targets for drug development.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.